Regeneron shares slide on mixed trial data for smoker's lung drug

Published on 05/30/2025 at 07:45 - Modifié on 05/30/2025 at 10:17

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sanofi

Sanofi: fast track designation in GA due to AMD	02:18am
Sanofi's Sar446597 Earns Fast Track Designation in the US for Geographic Atrophy Due Toage-Related Macular Debutation	01:50am	CI
Sanofi's Atrophy Treatment Receives US Fast-track Designation	01:19am	MT
Sanofi's SAR446597 earns fast track designation in US for geographic atrophy due to age-related macular degeneration	01:09am	RE
SANOFI : UBS reiterates its Buy rating	Jul. 11	ZD
Delaware Supreme Court sides with Zantac drugmakers over cancer evidence	Jul. 10	RE
Delaware Supreme Court sides with Zantac drugmakers over evidence	Jul. 10	RE
Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket	Jul. 10	MT
SANOFI : UBS maintains a Buy rating	Jul. 08	ZD
SANOFI : Goldman Sachs reiterates its Neutral rating	Jul. 03	ZD
Berenberg Keeps Sanofi at Buy on Expanding Pipeline Optionality	Jul. 03	MT
SANOFI : Gets a Buy rating from Berenberg	Jul. 03	ZD
AlphaValue/Baader Europe Cuts Sanofi Price Target Amid Pipeline Setbacks, Leadership Concerns	Jul. 02	MT
SANOFI : Barclays keeps its Buy rating	Jul. 02	ZD
SANOFI : JP Morgan remains Neutral	Jul. 02	ZD
SANOFI : Pipeline disappointments may push out the CEO	Jul. 01
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	Jul. 01	MT
Adagene ADRs Rise Following Sanofi Investment	Jul. 01	DJ
Adagene to Receive up to $25 Million Investment From Sanofi; Shares up Pre-Bell	Jul. 01	MT
SANOFI : UBS reaffirms its Buy rating	Jul. 01	ZD
Euroapi: sells Haverhill site in UK	Jul. 01
Esteve Pharmaceuticals, S.A. agreed to acquire Caprelsa® rights in more than 50 countries from Sanofi.	Jun. 30	CI
Sanofi Advances Rare Neurological Disorder Treatment with Orphan Drug Status in Japan	Jun. 30	MT
Sanofi Announces Riliprubart Granted Orphan Drug Designation in Japan for Chronic Inflammative Demyelinating Polyneuropathy	Jun. 30	CI
Sanofi: riliprubart designated orphan drug in Japan	Jun. 30